BRIEF—Sun Pharma ups offer for Taro Pharma

Indian drugmaker Sun Pharmaceutical has increased its bid to acquire Israeli generics firm Taro Pharma, up to $43 per share from its previous offer of $38 per share.

Sun Pharma is already a majority shareholder in Taro, which has significant interests in the USA and Canada.

The latest move comes several months after Sun Pharma's board offered a non-binding indication of interest to take full ownership of the firm.

At the end of the Indian fiscal year 2023, Sun Pharma reported income of 445 billion Indian rupees ($5.6 billion), up from 395 billion rupees in the previous year.